Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1977 1
1979 1
1980 1
1981 1
1985 1
1987 1
1989 2
1990 1
1991 1
1992 1
1993 2
1994 1
1995 1
1997 1
1998 1
1999 1
2003 1
2007 1
2008 2
2013 1
2015 1
2016 2
2017 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Pancreatic Alpha Cell Adenoma"
Page 1
Glucagonoma syndrome.
Bloom SR, Polak JM. Bloom SR, et al. Am J Med. 1987 May 29;82(5B):25-36. doi: 10.1016/0002-9343(87)90424-4. Am J Med. 1987. PMID: 2884877 Review.
The diagnosis is made by finding a high plasma glucagon concentration in the absence of any other cause, such as renal failure or severe stress. A pancreatic alpha-cell tumor can be identified and stained by immunocytochemistry with glucagon antibodies. ...Th …
The diagnosis is made by finding a high plasma glucagon concentration in the absence of any other cause, such as renal failure or severe str …
Somatostatin and the endocrine pancreas.
Gerich JE. Gerich JE. Curr Top Mol Endocrinol. 1976;3:127-43. doi: 10.1007/978-1-4684-2598-7_9. Curr Top Mol Endocrinol. 1976. PMID: 211005 Review.
Thus far, somatostatin has been used primarily as a research tool to investigate pancreatic alpha- and beta- cell function. On the basis of its ability to inhibit insulin and glucagon secretion, several therapeutic applications have been suggested: e.g., as a …
Thus far, somatostatin has been used primarily as a research tool to investigate pancreatic alpha- and beta- cell funct …
Medical treatment of neuroendocrine gut and pancreatic tumors.
Oberg K, Eriksson B. Oberg K, et al. Acta Oncol. 1989;28(3):425-31. doi: 10.3109/02841868909111217. Acta Oncol. 1989. PMID: 2472826 Review.
Surgery has always been considered to be the primary treatment in patients with neuroendocrine gut and pancreatic tumors, but a significant number of patients present liver metastases already at the first visit. ...In the third study, IFN-alpha 2b or IntronA was tes …
Surgery has always been considered to be the primary treatment in patients with neuroendocrine gut and pancreatic tumors, but a signi …
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Butler AE, et al. Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22. Diabetes. 2013. PMID: 23524641 Free PMC article.
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic beta-cells versus possible adverse pancreatic proliferative effects. ...In conclusion, incretin therapy in humans resulted in a marked expansion of the exocri …
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic beta-cells versus possibl …
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Ueberberg S, Jütte H, Uhl W, Schmidt W, Nauck M, Montanya E, Tannapfel A, Meier J. Ueberberg S, et al. Diabetes Obes Metab. 2016 Dec;18(12):1253-1262. doi: 10.1111/dom.12766. Epub 2016 Sep 26. Diabetes Obes Metab. 2016. PMID: 27545110
Alpha-cell area (P = .30), beta-cell replication (P = .17) and alpha-cell replication (P = .91) were not different. There were also no differences in acinar cell (P = .13) and duct cell replication (P = .099). Insulin-positive duct …
Alpha-cell area (P = .30), beta-cell replication (P = .17) and alpha-cell replication (P = .91) were not …
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, Wickstroem K, Schatz CA, Kneip C, Golfier S, Smeets R, Uran S, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Mumberg D, Ziegelbauer K, Cuthbertson AS. Hagemann UB, et al. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7. Clin Cancer Res. 2019. PMID: 31064781
PURPOSE: Targeted thorium-227 conjugates (TTC) represent a new class of molecules for targeted alpha therapy (TAT). Covalent attachment of a 3,2-HOPO chelator to an antibody enables specific complexation and delivery of the alpha particle emitter thorium-227 to tumo …
PURPOSE: Targeted thorium-227 conjugates (TTC) represent a new class of molecules for targeted alpha therapy (TAT). Covalent attachme …
Protein kinase C: a target for therapy in pancreatic cancer.
El-Rayes BF, Ali S, Philip PA, Sarkar FH. El-Rayes BF, et al. Pancreas. 2008 May;36(4):346-52. doi: 10.1097/MPA.0b013e31815ceaf7. Pancreas. 2008. PMID: 18437080
METHODS: Pancreatic tissue was obtained from 18 patients who had a resection (14 with ductal adenocarcinoma and 4 with adenoma and high-grade dysplasia). ...CONCLUSION: Protein kinase C is overexpressed and activated in pancreatic cancer as compared with norm …
METHODS: Pancreatic tissue was obtained from 18 patients who had a resection (14 with ductal adenocarcinoma and 4 with adenoma …
Therapeutic strategies in the management of endocrine GEP tumours.
Arnold R. Arnold R. Eur J Clin Invest. 1990 Oct;20 Suppl 1:S82-90. doi: 10.1111/j.1365-2362.1990.tb01782.x. Eur J Clin Invest. 1990. PMID: 1702388 Review.
Tumour growth might be controlled by surgical procedures as debulking of tumour masses, medically by chemotherapy and more recently by new developments as a long-acting somatostatin analogue (SMS 201-995) and alpha-interferon. Their efficacy is currently evaluated in prosp …
Tumour growth might be controlled by surgical procedures as debulking of tumour masses, medically by chemotherapy and more recently by new d …
Pancreatic alpha cell tumors: case report and review of the literature.
Lokich J, Anderson N, Rossini A, Hadley W, Federman M, Legg M. Lokich J, et al. Cancer. 1980 May 15;45(10):2675-83. doi: 10.1002/1097-0142(19800515)45:10<2675::aid-cncr2820451032>3.0.co;2-3. Cancer. 1980. PMID: 6247056
Twenty-eight cases of alpha cell tumors of the pancreatic islets have been reported. The clinical features include typical skin rash (termed migratory necrolytic erythema) and stomatitis with anemia, abnormal glucose tolerance, and weight loss. ...All …
Twenty-eight cases of alpha cell tumors of the pancreatic islets have been reported. The clinical features inclu …
A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
Saltz L, Kemeny N, Schwartz G, Kelsen D. Saltz L, et al. Cancer. 1994 Aug 1;74(3):958-61. doi: 10.1002/1097-0142(19940801)74:3<958::aid-cncr2820740326>3.0.co;2-x. Cancer. 1994. PMID: 8039124 Clinical Trial.
BACKGROUND: 5-Fluorouracil (5-FU) has shown modest single-agent activity in patients with carcinoid or islet cell tumors. Alpha interferon (alpha-IFN) has also shown modest single agent activity in these diseases, although biologic responses have been far mor …
BACKGROUND: 5-Fluorouracil (5-FU) has shown modest single-agent activity in patients with carcinoid or islet cell tumors. Alpha …
30 results